Skip to main content

Table 1 Genome-wide expression studies of LNs of breast carcinoma patients

From: Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients

Clinical questionStudyBreast carcinomaSample cohortResults
Scenario 1
Involved lymph node (ILN) versus primary tumours (PT)
Calvo et al. [36], 2013IDC18 PT vs matching ILNInfrequent loss of luminal differentiation in metastatic LN
Feng et al. [37], 2007IDC26 PT vs matching ILN79 DEG
Hao et al. & Lähdesmäki et al. [38, 39], 2004Invasive BC9 PT vs matching ILN280 DEG
Weigelt et al [40], 2005Invasive BC15 PT vs matching ILNNo classifier or single gene could discriminate
Ellsworth et al. [41], 2009Invasive BC20 PT vs matching ILN51 DEG
Vecchi et al. [42], 2008Invasive BC26 PT vs matching ILN270 DEG
Suzuki et al. [43], 2007Invasive BC10 PT vs matching ILN84 DEG
Scenario 2
Involved LN versus normal adjacent breast tissue (NAT)
Mathe et al. [44], 2015TNBC15 ILN vs 17 NAT83 genes were significantly associated with LN metastasis
Scenario 3
Uninvolved LN in LN-positive versus LN-negative patients
Zuckerman et al. [45], 2013Invasive BC11 PT, 30 LN, 21 PB116/219 DEG (SLN/NSLN, respectively)
Blackburn et al. [46], 2017Invasive BC24 LN from NP vs 40 LN from NNNo genes were differentially expressed with stringent FDR
Scenario 4
Uninvolved residual portion of involved LN versus uninvolved LN
Valente et al. [47], 2014Invasive BC20 matched pairs of involved and uninvolved LN22 DEG
Zuckerman et al. [45], 2013Invasive BC11 PT, 30 LN, 21 PB103 DEG
Scenario 5
Involved LN versus uninvolved LN
Rizwan et al. [48], 2015Invasive BC16 involved vs 3 uninvolved LN13 DEG
Scenario 6
Positive sentinel LNs in patients with additional, non-sentinel, positive LNs to patients with additional, non-sentinel, negative LNs
Liang et al. [49], 2015Invasive BC3 NSLN+ SLN vs 3 NSLN− SLN160 DEG
  1. BC breast carcinoma, DEG differentially expressed genes, IDC invasive ductal carcinoma (no special type), ILN involved LN, LN lymph node, NAT normal adjacent breast tissue, NN node-negative patients, NP node-positive patients, NSLN non-sentinel lymph node, PT primary tumour, SLN sentinel lymph node